Biotechnology is an important driver of innovation of the healthcare region Berlin-Brandenburg. The industry is experiencing steady growth and a high degree of start-up dynamics. Many of the biotech companies were founded from the universities and research facilities at the location. What’s known as “red” biotechnology, which deals with medicine, is particularly far ahead: Of the around 230 biotech companies with approximately 5,300 employees, almost 80% work in biomedicine. They are developing innovative therapeutic and diagnostic methods for the treatment of cancer, cardiovascular disease, and diabetes, benefiting from the strong science and infrastructure for clinical trials in the region. The expertise and local conditions make the German capital region attractive for globally active pharmaceutical companies: They can develop and produce novel active ingredients here.
First-class biomedical research landscape
In addition to drug development, bioanalytics, and diagnostics, the Berlin-Brandenburg region has developed into one of the most important German centers for regenerative medicine with outstanding fundamental biomedical and biomaterials research. Around 40 research institutes conduct research in the field of life sciences. One of the beacons in the biomedical research landscape with an appeal far beyond the region is the Berlin Institute of Health (BIH), where scientists from Charité and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)) conduct joint research and set new standards in systems medicine.